Investor Presentation First Nine Months of 2022

79 Investor presentation First nine months of 2022 Rare disease sales increased by 2%, driven by commercial execution and key brands EsperoctⓇ and Refixia® DKK billion 4% 20 20 10 10 0 2019 NovoSevenⓇ and NorditropinⓇ account for ~76% of Rare disease sales 1% 4% DKK billion 2% 4% 20 10 Rare disease franchise is back to growth 1% 4% 8 7 7 2% 6 11 12 12 10 0 2020 2021 9M 2022 2019 NovoSevenⓇ NorditropinⓇ Other haemophilia products¹ Other Rare disease Growth at CER Source: Quarterly company announcement Note: Company reported sales; CER: Constant exchange rates; 9M: 9 months; 1Other haemophilia products primarily consists of VagifemⓇ and ActivelleⓇ 2020 2021 9M 2022 IO NAO Growth at CER Novo NordiskⓇ

View entire presentation